Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder

No abstract is available for this paper.

• Publication year

  2011

• Venue

  NeuroRx

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.nurx.2005.12.006PMID 16490414PMCID PMC3593363
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neural circuitry and neuroplasticity in mood disorders: Insights for novel therapeutic targets

  2011cited by this paper
• Finding what you are not looking for: Strategies for developing novel treatments in psychiatry

  2011cited by this paper
• Advances in the treatment of anxiety: Targeting glutamate

  2011cited by this paper
• Exposure and Response Prevention.

  2007cited by this paper
• Visual hallucinations from the addition of riluzole to memantine and bupropion.

  2006cited by this paper
• Suppression of obsessive-compulsive symptoms after epilepsy surgery.

  2005cited by this paper
• A multidimensional model of obsessive-compulsive disorder.

  2005cited by this paper
• Glutamatergic Dysfunction in OCD

  2005cited by this paper
• Cystine/Glutamate Exchange Regulates Metabotropic Glutamate Receptor Presynaptic Inhibition of Excitatory Transmission and Vulnerability to Cocaine Seeking

  2005cited by this paper
• Topiramate related obsessive–compulsive disorder

  2005cited by this paper
• Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder.

  2005cited by this paper
• Association of temporal lobe epilepsy and obsessive-compulsive disorder in a patient successfully treated with right temporal lobectomy.

  2005cited by this paper
• Localized 1 H NMR measurements of y-aminobutyric acid in human brain in vivo

  2005cited by this paper
• N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder

  2005cited by this paper
• Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.

  2005cited by this paper
• Extracellular metabolites in the cortex and hippocampus of epileptic patients

  2005cited by this paper
• β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression

  2005cited by this paper
• Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

  2005cited by this paper
• An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.

  2005cited by this paper
• Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder

  2005cited by this paper
• The Role of Venlafaxine in the Treatment of Obsessive—Compulsive Disorder

  2005cited by this paper
• Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder.

  2005cited by this paper
• Deep brain stimulation for refractory obsessive-compulsive disorder.

  2005cited by this paper
• Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.

  2005cited by this paper
• Treatment of obsessive-compulsive disorder: cognitive behavior therapy vs. exposure and response prevention.

  2005cited by this paper
• Evidence-based pharmacotherapy of obsessive-compulsive disorder.

  2005cited by this paper
• Clinical practice. Obsessive-compulsive disorder.

  2004influential reference
• A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder.

  2004cited by this paper
• Treatment of compulsive hoarding.

  2004cited by this paper
• Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression.

  2004cited by this paper
• Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls.

  2004cited by this paper
• A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.

  2004cited by this paper
• A Review of the Treatment for Refractory Obsessive-Compulsive Disorder: From Medicine to Deep Brain Stimulation

  2004cited by this paper
• Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder.

  2004cited by this paper
• Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes).

  2004cited by this paper
• Neurosurgical interventions for neuropsychiatric syndromes

  2004cited by this paper
• Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

  2004cited by this paper
• Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder

  2004cited by this paper
• Riluzole Enhances Glutamate Uptake in Rat Astrocyte Cultures

  2004cited by this paper
• Riluzole augmentation for treatment-resistant depression.

  2004cited by this paper
• Pharmacotherapy for obsessive-compulsive disorder.

  2004cited by this paper
• Case report: successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine

  2004cited by this paper
• Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.

  2004cited by this paper
• An open-label trial of riluzole in patients with treatment-resistant major depression.

  2004cited by this paper
• Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study

  2004cited by this paper
• Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder

  2003cited by this paper
• Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse

  2003cited by this paper
• Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder.

  2003cited by this paper
• A placebo-controlled trial of risperidone in Tourette syndrome

  2003cited by this paper
• Obsessive-Compulsive Disorder: Development of Demand-Controlled Deep Brain Stimulation with Methods from Stochastic Phase Resetting

  2003cited by this paper
• Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder.

  2003cited by this paper
• Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders

  2003cited by this paper
• Long-Term Efficacy of Exposure and Ritual Prevention Therapy and Serotonergic Medications for Obsessive-Compulsive Disorder

  2003cited by this paper
• WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults

  2003cited by this paper
• Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

  2003cited by this paper
• Venlafaxine in treatment-resistant obsessive-compulsive disorder.

  2003cited by this paper
• Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.

  2003cited by this paper
• P.3.009 Cognitive-behavioral therapy in obsessive-compulsive disorder patients partially unresponsive to SRIs

  2003cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)

  2003cited by this paper
• Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function.

  2002cited by this paper
• Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study.

  2002cited by this paper
• Quetiapine augmentation in patients with treatment resistant obsessive–compulsive disorder: a single-blind, placebo-controlled study

  2002cited by this paper
• Risperidone in the Treatment of Tourette Syndrome: A Double-Blind, Placebo-Controlled Trial

  2002cited by this paper
• Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment

  2002cited by this paper
• Refractory obsessive-compulsive disorder: state-of-the-art treatment.

  2002cited by this paper
• Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.

  2002cited by this paper
• Riluzole enhances expression of brain‐derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus

  2002cited by this paper
• Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.

  2002cited by this paper
• A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry

  2002cited by this paper
• Magnetic Resonance Imaging-guided Stereotactic Limbic Leukotomy for Treatment of Intractable Psychiatric Disease

  2002cited by this paper
• Treatment non-response in OCD: methodological issues and operational definitions.

  2002cited by this paper
• Addition of cognitive‐behaviour therapy for obsessive‐compulsive disorder patients non‐responding to fluoxetine

  2002cited by this paper
• EMDR 12 years after its introduction: past and future research.

  2002cited by this paper
• Neuroprotective agent riluzole dramatically slows inactivation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism.

  2001cited by this paper
• Brain anatomy and chemistry may predict treatment response in paediatric obsessive--compulsive disorder.

  2001cited by this paper
• CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum.

  2001cited by this paper
• Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD.

  2001cited by this paper
• Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes.

  2001cited by this paper
• A review and meta-analysis of the genetic epidemiology of anxiety disorders.

  2001cited by this paper
• Symptom dimensions in obsessive-compulsive disorder: toward quantitative phenotypes.

  2001cited by this paper
• Introduction: antiscientific attitudes within psychotherapy: philosophical, scientific, and political/psychological considerations.

  2001cited by this paper
• Interaction of the neuroprotective drug riluzole with GABA(A) and glycine receptor channels.

  2001cited by this paper
• Increased Medial Thalamic Choline in Pediatric Obsessive-Compulsive Disorder as Detected by Quantitative in Vivo Spectroscopic Imaging

  2001cited by this paper
• Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine.

  2000cited by this paper
• Tourette's syndrome: when habit-forming systems form habits of their own?

  2000cited by this paper
• Tourette's Syndrome

  2000cited by this paper
• Riluzole inhibits the persistent sodium current in mammalian CNS neurons

  2000cited by this paper
• Proton spectroscopic imaging of the thalamus in treatment-naive pediatric obsessive-compulsive disorder.

  2000cited by this paper
• Effects of riluzole on electrically evoked neurotransmitter release

  2000cited by this paper
• A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.

  2000cited by this paper
• Neuroimaging research and the neurobiology of obsessive-compulsive disorder: where do we go from here?

  2000cited by this paper
• Lamotrigine Augmentation of Serotonin Re-Uptake Inhibitors in Obsessive–Compulsive Disorder

  2000cited by this paper
• Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder.

  2000cited by this paper
• Toward a neurobiology of obsessive-compulsive disorder.

  2000cited by this paper
• Altered cortical excitability in obsessive–compulsive disorder

  2000cited by this paper
• Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy.

  1999cited by this paper
• Last Resort: Psychosurgery and the Limits of Medicine

  1999cited by this paper
• Proton magnetic resonance spectroscopy of lenticular nuclei in obsessive–compulsive disorder

  1999cited by this paper
• Rapid remission of OCD with tramadol hydrochloride.

  1999cited by this paper
• OCD-Like Behaviors Caused by a Neuropotentiating Transgene Targeted to Cortical and Limbic D1+ Neurons

  1999cited by this paper

• Reconsidering the glutamate hypothesis of obsessive-compulsive disorder: A systematic review of proton magnetic resonance spectroscopy studies in unmedicated participants

  2026cites this paper
• Promising experimental drugs for obsessive-compulsive personality disorder

  2025cites this paper
• Innovative treatment approaches for paediatric obsessive-compulsive disorder

  2025cites this paper
• Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.

  2025cites this paper
• Efficacy of Topiramate in treating Obsessive Compulsive Disorder: a Systematic Review and Meta-analysis

  2024cites this paper
• Agranular frontal cortical microcircuit underlying cognitive control in macaques

  2024cites this paper
• Understanding cingulotomy’s therapeutic effect in OCD through computer models

  2023cites this paper
• Factors related to the severity of obsessive-compulsive symptoms and their impact on suicide risk in epileptic patients.

  2023cites this paper
• L‐theanine combination therapy with fluvoxamine in moderate‐to‐severe obsessive–compulsive disorder: A placebo‐controlled, double‐blind, randomized trial

  2023influential citation
• Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson’s Disease

  2023cites this paper
• The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders.

  2023cites this paper
• S-ketamine exerts sex- and dose-dependent anti-compulsive-like effect as monotherapy or in augmentation to fluoxetine.

  2022cites this paper
• Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial

  2022cites this paper
• Review of Obsessive Compulsive Disorders Theories

  2022cites this paper
• Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis

  2021cites this paper
• Pharmacotherapeutic Strategies and New Targets in OCD.

  2021cites this paper
• Computational Predictions for OCD Pathophysiology and Treatment: A Review

  2021cites this paper
• Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?

  2021cites this paper
• The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap

  2020cites this paper
• Obsessive–compulsive disorder

  2020cites this paper
• Anti-inflammatory Augmentation Therapy in Obsessive-compulsive Disorder: A Review

  2020cites this paper
• Neuromechanism in producing obsessions and compulsions: etiology and management criteria

  2020cites this paper
• Herbal Medicine in the Treatment of Obsessive Compulsive Disorder: A Review

  2019cites this paper
• A Psycho-Behavioral Perspective on Modelling Obsessive-Compulsive Disorder (OCD) in Animals: The Role of Context.

  2019cites this paper
• Integrating Cognitive Behavioral Therapy and Medications for the Treatment of Obsessive-Compulsive Disorder

  2019cites this paper
• The Glutamate and the Immune Systems: New Targets for the Pharmacological Treatment of OCD.

  2019cites this paper
• Central norepinephrine transmission is required for stress-induced repetitive behavior in two rodent models of obsessive-compulsive disorder

  2019cites this paper
• An MRI Study of the Metabolic and Structural Abnormalities in Obsessive-Compulsive Disorder

  2019cites this paper
• Neurochemicals, Behaviours and Psychiatric Perspectives of Neurological Diseases

  2018influential citation
• Decreased Serum Glutamate Levels in Male Adults with Internet Gaming Disorder: A Pilot Study

  2018cites this paper
• Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression

  2018cites this paper
• Obsesif Kompulsif Bozukluk Güçlendirme Tedavisinde Aripiprazol, Klomipramin ve Buspironun Etkinliği: Retrospektif Bir Araştırma

  2018cites this paper
• Obsessive-Compulsive Disorder

  2018cites this paper
• The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy)

  2018cites this paper
• Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive–compulsive disorder: A double‐blind randomized trial with placebo control

  2018cites this paper
• Epilepsy and concomitant obsessive–compulsive disorder

  2018cites this paper
• A critical inquiry into marble-burying as a preclinical screening paradigm of relevance for anxiety and obsessive–compulsive disorder: Mapping the way forward

  2018cites this paper
• Neurochemical and behavioral characterization of neuronal glutamate transporter EAAT3 heterozygous mice

  2017cites this paper
• Remission of obsessive-compulsive symptoms following temporoparietal haemorrhage: a case report

  2017cites this paper
• bsessive-compulsive disorder : Insights from animal models

  2017influential citation
• Biological Models and Treatments for Obsessive‐Compulsive and Related Disorders for Children and Adolescents

  2017cites this paper
• Efficacy of L-Cysteine as an Anti-Oxidant in Papain Catalyzed Synthesis ofOligopeptides in Organic Solvent System

  2017cites this paper
• The investigation of reward-based learning in obsessive-compulsive sub-clinical checkers.

  2017cites this paper
• Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal 1H-NMR spectroscopy study at 11.7T

  2017cites this paper
• Glutamate mGlu5 receptor antagonist, MPEP, reduces the quinpirole-induced compulsive-like checking in rats

  2017cites this paper
• The orbitofrontal cortex and emotion in health and disease, including depression.

  2017cites this paper
• Biological Basis of Behavior Program 10-7-2011 mGluR 5-Antagonist Mediated Reversal of Elevated Stereotyped , Repetitive Behaviors in the VPA Model of Autism

  2017cites this paper
• Effect of Religious Cognitive Behavioral Therapy on Religious Obsessive-compulsive Disorder (3 and 6 months Follow-up)

  2017influential citation
• Association between genetic variants of serotonergic and glutamatergic pathways and the concentration of neurometabolites of the anterior cingulate cortex in paediatric patients with obsessive–compulsive disorder

  2016cites this paper
• Minocycline combination therapy with fluvoxamine in moderate‐to‐severe obsessive–compulsive disorder: A placebo‐controlled, double‐blind, randomized trial

  2016cites this paper
• Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial

  2016cites this paper
• What Future Role Might N-Acetyl-Cysteine Have in the Treatment of Obsessive Compulsive and Grooming Disorders?: A Systematic Review

  2016cites this paper
• Management of obsessive-compulsive disorder comorbid with bipolar disorder

  2016cites this paper
• N‐acetylcysteine augmentation therapy for moderate‐to‐severe obsessive–compulsive disorder: randomized, double‐blind, placebo‐controlled trial

  2016cites this paper
• Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.

  2015cites this paper
• Use of N-acetylcysteine in Obsessive-Compulsive and Related Disorders

  2015cites this paper
• Diverse Glial Cell Line-Derived Neurotrophic Factor (GDNF) Support Between Mania and Schizophrenia: A Comparative Study in Four Major Psychiatric Disorders

  2015cites this paper
• Glutamatergic agents for OCD and related disorders

  2015cites this paper
• Glutamate modulators in the treatment of obsessive-compulsive disorder.

  2015cites this paper
• Neuromagnetic mismatch responses to auditory deviance during periods of threat and safe anticipation in patients with obsessive-compulsive disorder

  2015cites this paper
• Riluzole augmentation in treatment-refractory obsessive- compulsive disorder: a pilot placebo-controlled trial

  2015cites this paper
• Cerebral Cortex Principles of Operation

  2015cites this paper
• Role of Lamotrigine Augmentation in Treatment-Resistant Obsessive Compulsive Disorder: A Retrospective Case Review from South Asia

  2015influential citation
• Neuroimaging of psychotherapy for obsessive-compulsive disorder: A systematic review.

  2015cites this paper
• Non-Antidepressant Pharmacological Treatment of Obsessive Compulsive Disorder: A Comprehensive Review.

  2015cites this paper
• Marcadores genéticos y de neuroimagen en el Trastorno obsesivo-compulsivo de inicio en la infancia y la adolescencia

  2015cites this paper
• Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

  2015cites this paper
• Ceftriaxone prevents and reverses behavioral and neuronal deficits in an MPTP-induced animal model of Parkinson's disease dementia.

  2015cites this paper
• Cannabinoids and obsessive-compulsive disorder

  2015cites this paper
• The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human Positron Emission Tomography (PET) studies

  2015influential citation
• Assessment and management of treatment-refractory obsessive-compulsive disorder in children.

  2015cites this paper
• What future role might N-acetyl-cysteine have in the treatment of Obsessive Compulsive Spectrum disorders? A systematic review

  2015cites this paper
• Relationship Between Oxidative Stress and Obsessive - Compulsive Disorder

  2015cites this paper
• The Role of Serotonin in Orbitofrontal Function and Obsessive-Compulsive Disorder

  2015cites this paper
• A Genetic Association Study of Glutamate Transporter Genes SLC1A1 and SLC1A3 in Tourette Syndrome and Attention-Deficit/Hyperactivity Disorder

  2014cites this paper
• Potential role of anticonvulsants in the treatment of obsessive–compulsive and related disorders

  2014influential citation
• Metabotropic glutamate receptor 5 binding in patients with obsessive-compulsive disorder.

  2014influential citation
• Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model.

  2014cites this paper
• Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment

  2014cites this paper
• of Obsessive Compulsive Disorders Theories

  2014cites this paper
• Amantadine Augmentation Therapy for Obsessive Compulsive Patients Resistant to SSRIs—An Open-Label Study

  2014cites this paper
• Evaluating an Animal Model of Compulsive Hoarding in Humans

  2013cites this paper
• The role of the cholinergic system in the signal attenuation rat model of obsessive-compulsive disorder.

  2013cites this paper
• Actions of N-acetylcysteine in the central nervous system: implications for the treatment of neurodegenerative and neuropsychiatric disorders

  2013cites this paper
• Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.

  2013cites this paper
• Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors

  2013cites this paper
• The role of the cholinergic system in the signal attenuation rat model of obsessive-compulsive disorder

  2013cites this paper
• LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER

  2013cites this paper
• Glutamate-based anxiolytic ligands in clinical trials

  2013cites this paper
• Meta‐analysis of association between obsessive‐compulsive disorder and the 3′ region of neuronal glutamate transporter gene SLC1A1

  2013cites this paper
• An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder

  2013cites this paper
• Estudos de associação genética no transtorno obsessivo-compulsivo

  2013cites this paper
• The Developmental Neurobiology of Repetitive Behavior

  2013cites this paper
• Transcranial sonography in obsessive-compulsive disorder.

  2013cites this paper
• Emotion and decision-making explained: a précis.

  2013cites this paper
• Exploring the triad of behaviour, genes and neuronal networks: Heritability of instrumental conditioning and the Arc/Arg3.1 gene in hippocampal coding

  2013cites this paper
• Genetic association studies in obsessive-compulsive disorder

  2013cites this paper
• Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder.

  2012influential citation
• N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.

  2012cites this paper
• Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates.

  2012cites this paper